Open-label, randomized, phase 2 trial, we evaluated trastuzumab deruxtecan (T-DXd) as compared with chemotherapy in 187 adult patients with HER2-positive advanced gastric cancer. The gene discussed is ERBB2; the disease is gastric cancer.